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BACKGROUND Repeat revascularization following percutaneous
coronary intervention (PCI) is a common end-point in clinical studies
which may reﬂect restenosis, myocardial infarction or stent throm-
bosis events. However, the association between repeat revasculari-
zation and long-term mortality is poorly deﬁned. We explored the
relationship between target vessel revascularization (TVR) and long-
term mortality following PCI.
METHODS We analyzed mortality in 41,180 patients following their
ﬁrst index PCI procedure between 2008-2014 who were enrolled in the
British Columbia Cardiac Registry. Cox proportional hazard models
were built to determine the association between TVR (30 days, 1
month, 6 months, 1 year and 2 years) and long-term mortality at 3
years.
RESULTS A total of 5,554 patients (13.4%) received TVR during the
study period. The TVR rates for 30 days, 3 months, 6 months, 1 year
and 2 years were 2.4%, 3.4%, 4.9%, 6.6% and 8.5% respectively. The 3-
year mortality rates according to whether they had TVR versus no TVR
are shown in table 1. Multivariable-adjusted analyses identiﬁed TVR
at 30 days as a strong predictor for 3-year mortality (HR¼1.64, 95% CI:
1.36-1.98, p<0.001). This association persisted for TVR at 1 year
(HR¼1.17, 95% CI: 1.03-1.33, p¼0.013), but was lost for TVR at 2 years(HR¼1.07, 95% CI: 0.95-1.20, p¼0.269). The trends in HRs are shown in
ﬁgure 1.
CONCLUSIONS In this large cohort of unselected patients undergoing
PCI, early TVR was a strong independent predictor of long-term
mortality. This association became less strong with progressively later
TVR events. These data suggest that TVR events are not benign, and
might help explain late mortality events in clinical studies.
Table 1Follow-up periodCumulative TVR
rate (%)3 year mortality (%)TVR group No TVR group p value30 days 2.4 13.3 7.7 <0.0013 months 3.4 11.9 7.7 <0.0016 months 4.9 11.1 7.6 <0.0011 year 6.6 10.3 7.6 <0.0012 years 8.5 9.3 7.7 0.748CATEGORIES CORONARY: PCI Outcomes
KEYWORDS Mortality, long-term, Percutaneous coronary interven-
tion, Target vessel revascularization
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BACKGROUND The real world generalizability of clinical trials has
come under increasingly intense scrutiny. While patients participating
in clinical trials are of a lower risk proﬁle, they are followed up more
closely post percutaneous coronary intervention (PCI). We wanted to
discern whether enrollment in interventional cardiovascular clinical
trials translates to better or worse outcomes following PCI.
METHODS A single-center analysis was done of patients undergoing
PCI between 1/1/2010 and 12/31/2013 (n ¼ 14,075). Out of this cohort,
4.7% (n ¼ 659) were enrolled in a clinical trial. We compared those
enrolled versus not in clinical trials and analyzed for baseline and
procedural characteristics, death, myocardial infarction (MI), target
vessel revascularization (TVR), and major adverse cardiovascular
events (MACE).
RESULTS Patients enrolled in clinical trials were younger, had a bet-
ter left ventricular ejection fraction (LVEF), lower creatinine, and a
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to have calciﬁed lesions and more likely to have ACC/AHA Type C
lesions. The MACE rate was non-signiﬁcantly higher for patients
enrolled in a clinical trial versus not (12.6% versus 12.2%, p ¼ 0.8) as
was TVR (6.4% versus 5.6%, p ¼ 0.4). Patients enrolled in clinical trials
had a lower mortality after PCI (0.8% versus 4%, p < .001).
CONCLUSIONS Patients enrolled in clinical trials had a lower mor-
tality rate after PCI than those that were not. Whether this difference
is due to a lower risk proﬁle of this cohort, or the beneﬁts associated
with trial enrollment, including closer follow-up, warrants further
investigation.
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BACKGROUND Clinical trials in the United States tend to enroll
racially homogenous cohorts, thereby limiting generalizability. We
sought to identify correlates of clinical trial enrollment from a large
and racially diverse PCI registry.
METHODS We conducted a single-center study of patients undergoing
PCI between 1/1/2010 and 12/31/2013 (n¼14,075) at the Mount Sinai
Medical Center. We compared demographic, clinical and procedural
characteristics between patients who were and were not enrolled in
clinical trials during this period. Independent correlates of trial
enrollment were identiﬁed using multivariable logistic regression.
RESULTS Patients enrolled in trials (n¼659, 4.69%) were younger and
more likely to present with stable clinical syndromes compared to
their counterparts not enrolled (n¼13,416, 95.32%). African-Americans
and Hispanics were more frequently enrolled while Asians were less
likely to enter trials compared to Caucasians. In terms of PCI proce-
dural characteristics, the enrolled cohort was less likely to undergo
PCI of a saphenous vein graft and have thrombotic lesions (Table).Table. Baseline and procedural characteristics of patients enrolled in clinical trials versus not at Mount Sinai
Hospital, New York.p value Odds ratio95% Conﬁdence
IntervalAge 0.001 0.98 0.97-0.99Hispanics 0.042 1.32 1.01-1.73Prior MI 0.046 0.74 0.55-0.99Dialysis 0.015 0.23 0.07-0.76STEMI 0.005 0.16 0.04-0.57PCI-SVG 0.018 0.09 0.01-0.66Thrombosis 0.011 1.98 1.17-3.36MI: Myocardial Infarction; PCI-SVG: Percutaneous Coronary Intervention- Saphenous Vein Graft; STEMI: ST-
Segment Elevation Myocardial Infarction
CONCLUSIONS Patients enrolled in clinical trials differ substantially
from those not enrolled in terms of their baseline demographics,
clinical presentation, and procedural parameters, highlighting the
limited generalizability of trial results to real-world populations.
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BACKGROUND The 2-stenting technique has been regarded to show
worse clinical outcomes than the 1-stenting technique after bifurca-
tion PCI with 1st generation DES. However, there has been paucity of
data comparing 1- and 2-stenting techniques with the use of 2nd
generation DES. Therefore, we sought to investigate the differential
clinical outcomes after PCI for coronary bifurcation lesions with 1- or
2-stenting techniques using 1st or 2nd generation drug-eluting stent
(DES).
METHODS Patient-level pooled analysis was performed with 3,162
patients undergoing PCI using 1st or 2nd generation DES for bifurca-
tion lesions from the ’Korean Bifurcation Pooled Cohorts’ (COBIS II,
EXCELLENT, and RESOLUTE-Korea registry). The 3-year clinical out-
comes were compared between 1- and 2-stenting techniques, strati-
ﬁed by the type of DES.
RESULTS With 1st generation DES, rates of target lesion failure (TLF)
or patient-oriented composite outcome (POCO, a composite of all
death, any MI, any repeat revascularization, and cerebrovascular ac-
cidents) at 3-year were signiﬁcantly higher after 2-stenting than 1-
stenting technique (TLF: 8.6% vs. 17.5%, p<0.001; POCO 18.1% vs.
28.5%, p<0.001). With 2nd generation DES, however, there was no
difference between 1- and 2-stenting techniques (TLF: 5.4% vs. 5.8%,
p¼0.768; POCO: 11.2% vs. 12.9%, p¼0.995). The differential impacts of
2-stenting technique on the prognosis according to the type of DES
were also corroborated with similar results by the inverse probability
weighted model. The 2-stenting technique was a signiﬁcant inde-
pendent predictor of TLF in 1st generation DES (HR 2.046, 95% CI
1.114-3.759, p<0.001), but not in 2nd generation DES (HR 0.667, 95%
CI 0.247-1.802, p¼0.425).
